ABT Share Price | Abbott Laboratories Stock Analysis & Recommendation

Q: How big is Abbott Laboratories?

Market Cap: As of Jun 18, Abbott Laboratories has a market capitalization of 258,561.54 million, classifying it as a Large Cap company.Recent Quarterly Performance: For the latest four quarters, Abbott Laboratories reported net sales of 42,344.00 million and a net profit of 13,432.00 million.Balance Sheet Snapshot: As of Dec'24, the company's shareholder's funds amounted to 47,664.00 million, while total assets were reported at 81,414.00 million.

Q: What does Abbott Laboratories do?

Overview:Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products within the Pharmaceuticals & Biotechnology industry, categorized as a large-cap company.Financial Snapshot:Most recent Net Sales: 10,358 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 1,300 Million (Quarterly Results - Mar 2025) Market cap: USD 258,561.54 Million (Large Cap)Key Metrics:P/E: 19.00 Dividend Yield: 0.00% Debt Equity: 0.13 Return on Equity: 27.70% Price to Book: 5.30 Contact Details:Address: 100 Abbott Park Rd, ABBOTT PARK IL: 60064-3500 Tel: 1 224 6676100 Website: https://www.abbott.com

Q: Who are in the management team of Abbott Laboratories?

As of March 2022, the management team of Abbott Laboratories includes the following individuals:- Mr. Miles White, who serves as the Executive Chairman of the Board.- Mr. Robert Ford, who is the President, Chief Executive Officer, and Director.- Mr. William Osborn, who holds the position of Lead Independent Director.- Dr. Robert Alpern, who is an Independent Director.- Ms. Roxanne Austin, who is also an Independent Director.- Ms. Sally Blount, serving as an Independent Director.- Ms. Michelle Kumbier, who is another Independent Director.This team plays a crucial role in guiding the company's strategic direction and operations.

Q: Is Abbott Laboratories technically bullish or bearish?

As of 10 October 2025, the technical trend for Abbott Laboratories has changed from bullish to mildly bullish. The weekly MACD indicates a mildly bearish stance, while the monthly MACD remains bullish. The daily moving averages are bullish, suggesting short-term strength. The Bollinger Bands show a sideways trend on the weekly chart and mildly bullish on the monthly chart. The KST is bullish on both weekly and monthly time frames, but the OBV is mildly bearish weekly and shows no trend monthly. Overall, the technical stance is mildly bullish, driven primarily by the monthly MACD and KST indicators.In terms of multi-period returns, Abbott has outperformed the S&P 500 year-to-date with a return of 16.15% compared to the S&P's 11.41%, but has lagged over longer periods such as the 3-year and 5-year returns.

Q: Is Abbott Laboratories overvalued or undervalued?

As of 21 November 2025, the valuation grade for Abbott Laboratories has moved from very attractive to attractive. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 19, an EV to EBITDA of 25.84, and a PEG ratio of 0.14, indicating strong growth potential relative to its price.In comparison to its peers, Abbott Laboratories has a more favorable P/E ratio of 18.36 compared to Thermo Fisher Scientific's 30.06 and Medtronic's 21.47, suggesting that it is priced more competitively within the industry. Despite a recent decline in stock price, Abbott has outperformed the S&P 500 year-to-date with a return of 12.45% compared to the index's 12.26%, although it has lagged significantly over the longer three and five-year periods.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.63 M

Shareholding (Dec 2025)

FII

16.79%

Held by 609 FIIs

DII

51.11%

Held by 177 DIIs

Promoter

0.18%

How big is Abbott Laboratories?

22-Jun-2025

As of Jun 18, Abbott Laboratories has a market capitalization of $258.56 billion, with recent net sales of $42.34 billion and a net profit of $13.43 billion.

View full answer

What does Abbott Laboratories do?

22-Jun-2025

Abbott Laboratories is a large-cap company that develops and sells a wide range of healthcare products in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $10.36 billion and a net profit of $1.3 billion, with a market cap of approximately $258.56 billion.

View full answer

Who are in the management team of Abbott Laboratories?

22-Jun-2025

As of March 2022, Abbott Laboratories' management team includes Executive Chairman Miles White, CEO Robert Ford, Lead Independent Director William Osborn, and Independent Directors Robert Alpern, Roxanne Austin, Sally Blount, and Michelle Kumbier. They are responsible for guiding the company's strategic direction and operations.

View full answer

Is Abbott Laboratories technically bullish or bearish?

14-Oct-2025

As of October 10, 2025, Abbott Laboratories shows a mildly bullish technical trend, supported by a bullish monthly MACD and KST, while year-to-date it has outperformed the S&P 500 with a 16.15% return, though it has lagged in 3- and 5-year returns.

View full answer

Is Abbott Laboratories overvalued or undervalued?

25-Nov-2025

As of November 21, 2025, Abbott Laboratories is rated as attractive, fairly valued with a P/E ratio of 19, and has outperformed the S&P 500 year-to-date, despite a recent stock price decline and underperformance over the past three to five years.

View full answer

Compare Abbott Laboratories with Similar Stocks

Thermo Fisher Scientific, Inc.Danaher Corp.Stryker Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.62 times

Healthy long term growth as Operating profit has grown by an annual rate 13.45%

The company has declared Positive results for the last 3 consecutive quarters

With ROCE of 13.01%, it has a attractive valuation with a 4.85 Enterprise value to Capital Employed

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 214,677 Million (Large Cap)

P/E

32.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.10

Return on Equity

0.00%

Price to Book

0.00

Revenue and Profits:

Net Sales:

11,459 Million

(Quarterly Results - Dec 2025)

Net Profit:

1,800 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-14.33%

6 Months

-20.35%

1 Year

-15.13%

2 Years

-4.67%

3 Years

10.49%

4 Years

-12.46%

5 Years

-9.25%

Abbott Laboratories for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

5.08%

EBIT Growth (5y)

9.38%

EBIT to Interest (avg)

17.68

Debt to EBITDA (avg)

0.62

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

4,433.45

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

64.34%

Pledged Shares

Institutional Holding

81.30%

ROCE (avg)

151,913.83%

ROE (avg)

280,862.97%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

EV to EBIT

25.91

EV to EBITDA

20.24

EV to Capital Employed

EV to Sales

4.84

PEG Ratio

Dividend Yield

ROCE (Latest)

ROE (Latest)

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 240 Schemes (31.9%)

Foreign Institutions

Held by 609 Foreign Institutions (16.79%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 0.79% vs 2.04% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 12.50% vs -11.11% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "11,459.00",
          "val2": "11,369.00",
          "chgp": "0.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3,162.00",
          "val2": "2,954.00",
          "chgp": "7.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "135.00",
          "val2": "121.00",
          "chgp": "11.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-37.00",
          "val2": "-84.00",
          "chgp": "55.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,800.00",
          "val2": "1,600.00",
          "chgp": "12.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "206.80%",
          "val2": "190.30%",
          "chgp": "1.65%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 5.67% vs 4.59% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -51.31% vs 134.19% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "44,328.00",
          "val2": "41,950.00",
          "chgp": "5.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "11,380.00",
          "val2": "10,069.00",
          "chgp": "13.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "525.00",
          "val2": "603.00",
          "chgp": "-12.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-170.00",
          "val2": "2.00",
          "chgp": "-8,600.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "6,500.00",
          "val2": "13,351.00",
          "chgp": "-51.31%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "186.40%",
          "val2": "163.30%",
          "chgp": "2.31%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

11,459.00

11,369.00

0.79%

Operating Profit (PBDIT) excl Other Income

3,162.00

2,954.00

7.04%

Interest

135.00

121.00

11.57%

Exceptional Items

-37.00

-84.00

55.95%

Consolidate Net Profit

1,800.00

1,600.00

12.50%

Operating Profit Margin (Excl OI)

206.80%

190.30%

1.65%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 0.79% vs 2.04% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 12.50% vs -11.11% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

44,328.00

41,950.00

5.67%

Operating Profit (PBDIT) excl Other Income

11,380.00

10,069.00

13.02%

Interest

525.00

603.00

-12.94%

Exceptional Items

-170.00

2.00

-8,600.00%

Consolidate Net Profit

6,500.00

13,351.00

-51.31%

Operating Profit Margin (Excl OI)

186.40%

163.30%

2.31%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 5.67% vs 4.59% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -51.31% vs 134.19% in Dec 2024

All Annual Results

Company CV

About Abbott Laboratories

Abbott Laboratories

Pharmaceuticals & Biotechnology

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Company focuses on cardiovascular, diabetes care, diagnostics, neuromodulation, nutrition and medicine. It offers products, including FreeStyle, PediaSure, Pedialyte, Similac, EleCare, ZonePerfect, Juven, Ensure and Glucerna. The Company’s products are sold directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. The cardiovascular's products include Portico, MitraClip, Dilatation Catheter, among others. The diagnostics products include IntelliFISH, Vysis ALK, STARLIMS, PathVysion, AlinIQ, among others.

Company Coordinates

Company Details

100 Abbott Park Rd , ABBOTT PARK IL : 60064-3500

Tel: 1 224 6676100

https://www.abbott.com

Registrar Details